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ABSTRACT 
The World Health Organization (WHO) has estimated that about 3% of the world’s 
population is currently infected with Hepatitis C Virus (HCV). Although spontaneous clearance 
of HCV infections occurs in 10-20% of patients, nearly 185 million people are still chronically 
infected by HCV, which is one of the leading risk factors for developing liver cirrhosis and/or liver 
cancers. In the HIV-1 infected population, chronic HCV infection has become one of the leading 
causes of non-AIDS specific morbidity and mortality. In the United States about 25% of HIV-1 
positive individuals have co-infections with HCV. It has been observed that HIV-1 infection 
reduces the rate of spontaneous clearance and exacerbates the clinical course of HCV infection in 
HIV/HCV co-infected individuals, but the mechanisms driving this remain unknown. One of the 
major hurdles of studying the mechanisms of HCV infection over the last two decades has been 
the inability to grow and study this virus in a laboratory setting, as well as, the inability to develop 
reliable animal models. The development of the HCV pseudotyped viral particles (HCVpp) system 
was ground-breaking and became one of the most important in vitro study tools to test the 
neutralizing antibodies against virus entry and vaccine studies. Therefore, we used HCVpp to 
evaluate the role of neutralizing antibodies in an HIV-infected subject who spontaneously cleared 
HCV, but subsequently was re-infected with a different genotype of HCV. 
In this study, we examined the role of HCV specific neutralizing antibodies in HCV 
clearance and chronicity in a HIV/HCV co-infected subject who was enrolled in Pittsburgh portion 
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of the Multicenter AIDS Cohort Study (MACS). The subject’s records showed a 10year history of 
HIV infection and treatment with antiretroviral drugs for 2 years prior to HCV infection. 
According to our previous studies, this person was consecutively infected with two different 
genotypes of HCV. By sequence analysis, the initial infecting HCV genotype was 3a and the 
subsequent infecting genotype, 1.5 years later, was HCV 1a. Sequence analysis of HCV with 
longitudinal samples from this individual shows that the initial infecting HCV 3a was cleared 
spontaneously after one and half year infection, but after the subsequent infecting HCV 1a 
established its chronic infection in this individual. 
We hypothesized that neutralizing antibodies played an important role in controlling and 
clearing the HCV 3a infection, but had minimal impact on the HCV 1a infection. Using HCVpp 
containing autologous envelope proteins of HCV subtype 3a or 1a, we measured the neutralization 
activity of antibodies present in the subject’s serum. We found that after pre-incubating genotype 
3a specific HCVpp with the subject’s serum collected 6 months after HCV 3a infection, there was 
a tendency of reduction in the genotype 3a specific HCVpp infectivity. However, we observed no 
reduction in infectivity of genotype 1a specific HCVpp, which were pre-incubated with the 
subject’s serum collected after HCV 1a infection. Therefore, our results suggest that the 
development and presence of neutralizing antibodies may be important for the spontaneous 
clearance of HCV 3a in HIV co-infected individuals. This study contributes to our understanding 
of immune control of HCV, which may lead to the development of preventive vaccine against 
HCV and have a great Public Health impact in preventing HCV infection. 
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1.0  INTRODUCTION 
1.1 VIRAL HEPATITIS C INFECTION 
1.1.1 HCV DISEASE BURDEN AND CURRENT ADVANCES  
Chronic HCV infection is one of the leading causes of liver disease, cirrhosis and 
hepatocellular carcinoma. The prevalence of HCV according to 2014 WHO estimates is 
approximately 170-185 million worldwide with a US disease burden of about 4 million [1]. HCV 
is mainly spread by blood-blood contact with the primary routes of infection being injection-drug 
use and unscreened blood products used in transfusions. Until recently, the only “gold standard” 
treatment option available was pegylated interferon (pegIFN) and ribavirin, but this treatment was 
only effective in 40-80% of the HCV infected patients and carried many side effects [6, 7]. The 
latest developments in HCV antiviral drugs have been very promising.  In 2011, protease inhibitors 
Boceprevir (Merck) and Telaprevir (Vertex) were approved by the FDA and are currently being 
used in a combination with pegIFN and ribavirin (ref). This combinational therapy has increased 
the rate of HCV clearance to 70-80% in treated patients. Another wave of new direct acting agents 
(DAAs), with an observed clearance rate of 90-99%, will be  approved for treatment by 2015. It is 
predicted that these new DAAs will decrease the burden of HCV infection to half within 10-15 
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years [8]. However, there is still no preventive vaccine available, which still should be a priority 
to prevent and control the spread of HCV.  
1.1.2 HCV GENOME STRUCTURE 
 
 
Figure 1. HCV Genome structure and viral proteins. 
The HCV genome is ~9.6kb long with a single open reading frame that’s translated into a single polypeptide. Co- and 
post-translationally this polypeptide is cleaved at specific sites to produce 10 viral proteins. There are 3 structural 
proteins (Core, E1, E2, p7) and six non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B).  
 
Hepatitis C virus is an enveloped, single-stranded positive sense RNA virus, that is the 
only member of the hepacivirus genus of the Flaviviridae family [9]. The genome is ~9.6 kilobases 
and contains 5’ and 3’ untranslated regions (UTR) that have important RNA structures required 
for replication. There is an internal ribosomal entry site (IRES) at the 5’ UTR that forms a stable 
Adopted from google.com images  
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pre-initiation complex required for efficient translation of the HCV 3000 amino acid long 
polyprotein. This polypeptide is cleaved by both cellular and the viral proteases to make 3 
structural proteins, the envelope proteins E1 and E2, the core protein, p7, and six of non-structural 
proteins NS2, NS3, NS4A, NS5A and NS5B. NS5B. The first protein to be cleaved from the 
polyprotein is the 21kDa core protein that forms the nucleocapsid and is responsible for packaging 
the viral RNA. Between the core and E1 envelope protein is a signaling sequence that targets the 
polyprotein to the endoplasmic reticulum (ER). At the ER, the E1 protein is cleaved and 
translocated in the ER lumen for further post-translational processing and glycosylation. The 
envelope glycoprotein E1 and E2 are the essential components of the HCV virion and play an 
essential role in entry and fusion [10]. The p7 and NS2 proteins are thought to be important in the 
assembly of the virion. NS3 contains helicase activities that are essential for viral RNA replication 
and the NS5B contains the RNA-dependent RNA-polymerase, which is also an essential 
requirement for HCV genome replication. Both of these non-structural proteins have been ideal 
targets for current DAAs [11].  
Initial attachment of the virus to hepatocytes requires cellular lipoproteins such as low 
density lipoproteins and apo-E proteins [12]. The essential cellular attachment molecules for HCV 
are CD81, scavenger receptor class B member (SRBI), claudin 1(CLDN1), occludin (OCLN) and 
cholesterol absorption receptor Niemann-Pick C1-like 1 (NPC1L1). HCV Envelope protein E2 
(HCV E2) directly binds to CD81, which is the main receptor that defines the tropism of HCV in 
human cells[13]. Many studies have shown that HCV E2 selectively binds with high affinity to 
CD81 in humans and chimpanzees[14]. Experimentally, blocking HCV E2 binding using an anti-
CD81 antibody prevents the infection of cells in culture using HCVpp[15]. This experiment is part 
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of our rationale for investigating neutralizing antibodies that could prevent HCV attachment and 
entry by interfering with HCV binding to cellular receptors.   
1.1.3 HCV GENOTYPE DIVERSITY 
In 1989, investigators at the CDC identified HCV and shortly thereafter that same year 
sequenced and published its complete genome. Since the identification of HCV, investigators have 
been isolating and sequencing HCV from infected patients to build a data set of HCV genomic 
sequences, which can be accessed from the HCV Sequence Database 
(http://s2as02.genes.nig.ac.jp/).  After isolating HCV from many patients with a variety of disease 
outcomes and from different geographical locations, it was observed that HCV is highly 
heterogeneous in nature [16]. The updated consensus of HCV classification in 2013 categorizes 
HCV into 7 major genotypes and 67 subtypes (Figure 2). Genotypes 1a and 1b are the most 
common genotypes, accounting for 60%-70% of all HCV infections worldwide. HCV infection 
with genotypes 1a or 1b is difficult to treat because the standard pegIFN and ribavirin regimen is 
not very effective overall. Genotype 3a and 2 are responsible for 20-25% of HCV infections in the 
US, but patients infected with these genotypes are twice likely to clear the infection while on the 
standard treatment regimen compared to those infected with genotypes 1a and 1b. Therefore, there 
is a poor prognosis for patients infected with HCV genotype 1 despite receiving the standard 
interferon treatment [17]. Sequence similarity among the different genotypes varies from 66% to 
80%. There are three levels of genomic variations: types, subtypes, and quasispecies. The HCV 
genomes differ from 31-34% among genotypes, 21-23% among subtypes and 8-9% among 
quasispecies[18]. The HCV quasispecies found in a single individual are closely related to the 
original HCV genotype that established the initial infection. Due to selective pressure from the 
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host immune system and other factors, the virus evolves by inducing escape mutations to prevent 
recognition and neutralization [17]. These minor genetic mutations that occur spontaneously over 
time create many different quacispecies within the individual, but the genotype does not change. 
However, in some cases, individuals who receive multiple blood transfusions, under hemodialysis 
or who are IV-drug users can be infected with more than one genotype. This condition is referred 
to as a mixed-genotype infection [19].  
 
 
 
Figure 2. HCV genotype distribution in the US.  
The most prevalent genotype 1a accounts for about 60% of all HCV infection cases. 
 
HCV genotypes differ in their geographical distribution worldwide. In the United States, more 
than 60% of HCV infections are caused by HCV genotypes 1a (Figure 2), whereas in other parts 
of the world the HCV burden of disease may be caused by a different HCV genotype [20]. For 
60.30%16.70%
11.30%
9.60% 1.20% 0%1.50% Genotype 1aGenotype 1bGenotype 2Genotype 3Genotype 4Genotype 5Genotype 6
Adopted from google.com images  
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example, in Egypt HCV infections are only caused by genotype 4a while in South Africa HCV 
infections are only caused by genotype 5a [21].  
 
1.1.4 HCV STUDY SYSTEMS 
It was discovered in the 1980s that there was another virus other than Hepatitis A and B 
that was causing liver damage in individuals, but the etiological agent, HCV, wasn’t discovered 
until 1989[22]. The discovery of hepatitis C virus was very difficult because isolating and growing 
this virus in culture is challenging, which has been a major hindrance in studying this new 
relatively new virus. Until 2005, there was no efficient method for growing and studying the 
replication of HCV in a cell culture system[23]. Many attempts have been taken to overcome the 
roadblocks in this field, but a lot of work still needs to be done to  improve the current systems. 
One of the current available systems for in vitro study of HCV is using the human hepatoma cell 
line, Huh-7, which  are transfected with genomic HCV RNA that is package and released as 
infectious HCV particles [4]. Although far from a perfect system due to limitations of the virus’s 
ability to spread in  culture cells, this is a major advancement that has significantly improved the 
ability to study HCV entry into host cells and replication.  
Since HCV infection and replication are restricted to liver cells, the Huh-7 cell line, an 
immortal cell line derived from human hepatocyte cellular carcinoma, is the best permissive cell 
for HCV infection study in vitro[24]. Recent developments of self-replicating RNA’s (HCV 
replicons) and a robust propagating cell culture system have made it possible to study the virus life 
cycle and DAA agents [25]. The lack of reliable and convenient animal models is still a major 
obstacle in the study of immune responses specific for HCV infections. The only available reliable 
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animal model is the chimpanzee, but the drawbacks to this model are ethical issues and economic 
costs. [26]. A newly developed transgenic mouse model that expresses HCV genes in the liver has 
provided a convenient model to study HCV pathogenesis [25]. However, this transgenic mouse 
model is not ideal to study immune responses during HCV infections because mice do not support 
HCV infection. Another available mouse model is the immunodefficient murine model SCID-Alb-
uPA chimeric mice with xenografted human liver, which provides a good model to study virus 
entry and fitness, but the limitations for immunological studies is the need for the mice to have the 
same HLA type as the transplanted hepatocytes [27, 28]. Another system for studying HCV in 
vitro is HCV pseudovirual particle (HCVpp). After the development of HCVpp, scientists were 
able to study virus entry and neutralizing antibody responses during HCV infections[4]. HCVpp 
containing structural proteins of various HCV genotypes enable scientists to investigate humoral 
and cellular immune responses, and to expand their study objectives to encompass protective 
vaccine development against HCV infections.  
1.2 IMMUNE RESPONSE DURING HCV INFECTION 
1.2.1 HCV AND INNATE IMMUNE RESPONSE 
The main characteristic of HCV infection is its ability to silently induce chronic infections 
such that most patients are unaware they have been infected. Even though about 30-50% of 
hepatocytes are infected with HCV, the infected cells exist in clusters around the liver, which 
suggests that the virus is transmitted from cell to cell [29]. The first line of defense against HCV 
is initiated by the innate immune system that recognizes specific HCV RNA structures by RNA-
 7 
dependent protein kinase R (PKR) or by RIG-I within the cytosol[30]. Recognition of a foreign 
invader by these sentries results in the activation of interferon regulatory factor-3 (IRF-3), which 
in turn activates the production of type I IFNs. This, in turn, induces a robust IFN response against 
the invading HCV. However, the main cellular source of IFN production is not clear, some 
investigators suggest that infected hepatocytes are the first cells to produce IFNs[30]. Then other 
cells and immune cells in response to this initial IFN production also induce IFN production and 
signaling [31].  Within the infected hepatocytes, RIG-I is thought to sense HCV RNA and activate 
caspases, which interacts with a mitochondrial membrane protein (MAVS) to mediate IRF-3, IRF-
7 and NF-kB activity. However, the viral proteases NS3/NS4A not only processes the viral 
polypeptide, but also blocks RIG-I mediated signaling by cleaving off the MAVS (or also called 
IPS-1). This is an immune escape mechanisms used by the virus to block the induction of an anti-
viral IFN-response [32].  
There is evidence that hepatocytes are not the only cells producing type I and type II IFNs 
in response to HCV infection because liver specific macrophages, called Kupffer cells, have also 
been observed to express IFN- β. Conventional dendritic cells (DCs) can also be responsible for 
the production of IFN- β. Through TLR3 signaling, DCs recognize dsRNA and initiate the 
production of IFN- β by recruiting TRIF (Toll/IL-1 receptor domain-containing adaptor inducing 
IFN-β), which further activates downstream signaling to activate NF-kB, IRF-3 and IRF-7 genes 
[33]. Viral proteases NS3/NS4A, as a means of immune evasion, abrogate this pathway by the 
cleavage of TRIF. This blocks the IFN signaling process and shuts down any IFN-response against 
HCV.  These mechanisms of blocking IFN production during HCV infection could partially 
explain the impairment of IFN- α, β induction, but still it is not clear how HCV still persists under 
a robust immune response and interferon therapy [32]. Recent studies have shown that genetic 
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alteration of InterferonL3 (IFNL3) gene is associated with spontaneous clearance and interferon-
based treatment outcome of HCV infection [34]. However, the mechanism of the Single 
Nucleotide Polymorphism (SNP) of IFNL3 gene is still not well understood. In the HCV infected 
patients with the rs12979860 CC-variant of IFNL3 gene, which is more prevalent in Asians and 
Europeans, there is a good prognosis when treated with the standard interferon treatment, whereas 
with other variants of IFNL3, such as the rs4803217 SNP TT variant, the prognosis for clearance 
isn’t as promising [35].  
The main players of innate immune response in liver are Natural Killer cells (NK), NKT 
cells and cell subsets from myeloid lineage including Kupffer cells. During HCV infection, the 
role of NKT cells is not well understood and there are some studies the report T cell functions are 
altered by the production of IL-10 and TGF- β [36]. NK cells are the key early responders during 
HCV infection [37]. They control viral infection by producing IFN-γ, lysing the HCV infected 
cells, and stimulating DC maturation. DC functions are impaired during HCV infections so they 
are unable to efficiently present viral antigens, which have a detrimental effect on mounting an 
effective adaptive immune response. Some authors speculate that this impairment of DCs is caused 
by HCV infection of these cells leading to a failure to properly mature. However, to date, no viral 
RNA has been detected within DCs isolated from infected animals [30]. Thus, the role innate 
immunity plays in protecting against HCV infections is not well understood, but there still a strong 
cause for the role certain IFNL3 gene in play in predicting successful outcomes to interferon 
therapy. 
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1.2.2 THE ROLE OF CELLULAR AND HUMORAL IMMUNE RESPONSE  
Although the innate immune response and IFN production are very important during the 
early phase of HCV infection, HCV clearance requires a robust adaptive immune response. 
Numerous studies have reported the important role CD4+ T cell play in spontaneous clearance of 
HCV [38]. Usually HCV remains asymptomatic during the initial stages of infection. However, if 
the person develops signs and symptoms of an acute HCV infection, it usually corresponds 
strongly to eventual viral clearance.  Studies have been performed to investigate how the immune 
system responds to acute HCV infection in the patients with a known time of exposure to HCV 
and in chimpanzee models [39]. Even in the presence of a high viral load, there are usually no 
symptoms of liver damage. HCV specific T cell responses can be detected earlier compared to 
HCV specific neutralizing antibodies. About 8-12 weeks after infection, an increase of liver 
transaminases in the blood indicates that there is a strong cytotoxic T cell activity against the 
infected hepatocytes, as shown in Figure 3A [40]. It has been reported that spontaneous clearance 
of HCV is related a robust T cell response, which targets multiple HCV epitopes [41]. An early 
CD4 T cell response is a strong marker used to predict the control of an acute HCV infection. In 
the absence of this robust response T-cell response, viremia levels rebound and a persistent 
infection is established [42]. A unique characteristic of HCV infections is the late development of 
the adaptive immune response. For 8-12 weeks post-infection, there is only an innate immune 
response detected by ISG’s in the blood. The CD4+ and CD8+ T cell response wouldn’t be 
detected until after the development of the acute stage of HCV infection. HCV-specific 
neutralizing antibodies appear even later about 16-18 weeks after onset of the initial infection and 
their appearance is usually followed by the resolution of HCV[43] . It has been reported that the 
small portion of patients who had self-limiting HCV infections mounted broad CD4+ T cell 
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responses during the acute phase and had high levels of Il-2, TNF-α and IFN-γ, which are important 
cytokines for T-cell survival and proliferation[44].  
Longitudinal studies have shown that there are a number of HCV epitopes targeted by T 
cells are similar between individuals who develop chronic infections and individuals who clear 
infections [45]. In an established chronic infection, the number of HCV specific CD8 T cells may 
be abundant, but they are not able to control the virus [46]. After the establishment of initial 
infection, about 36-38 weeks, escape mutants from neutralizing antibodies start to appear as well 
as escape mutations that can escape T cell activities, as shown in Figure 3B[43]. 
HCV evades the host’s adaptive immune response, particularly the neutralizing antibodies 
(nAb), to establish chronic infections. Numerous studies have focused on T cell immunity and 
viral escape mutants [47], but the role of neutralizing antibodies in HCV clearance is not 
completely understood and is not very well studied. Vaccination studies performed on 
chimpanzees have shown they can successfully mount an HCV specific immune response [48]. 
According to previous studies on chimpanzees, the HCV E2 protein contains an extremely 
hypervariable region I (HVR1), which is a major target for nAb and high concentrations of HVR1 
specific nAb in the serum are required to effective neutralize the virus [49]. This region is also 
important for receptor binding and disease outcome. Many studies focused on HVR1 epitopes have 
found that it varies between different HCV genotypes.  HVR1 seems to mask nAb epitopes within 
the E2 protein as mutation studies within the HVR1 region made HCV more susceptible for 
neutralization [50], [25]. There is strong evidence that nAb responses against E1/E2 epitopes could 
be protective as it has been associated with the resolution of HCV in some studies [51]. Even 
though, many studies focus mainly on the role of T cells in HCV clearance, the importance of the 
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neutralizing antibody responses should not be underestimated and should be the focus of more 
future studies. 
A. 
 
 
B. 
 
 
Figure 3 Clinical, Virological, and Immunological course of Acute HCV infection.  
A. Acute hepatitis C followed by recovery. B. Acute hepatitis C followed by chronic infection.  
Figures adopted with permission from Immunity, Volume 40, Issue 1, 2014, 13 – 24, Su-Hyung  Park , Barbara 
Rehermann 
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1.3 HIV/HCV COINFECTION 
1.3.1 TRANSMISSION AND EVOLUTION OF HIV AND HCV 
Human immunodeficiency virus (HIV) is an envelope RNA retrovirus that has overlapping 
routes of transmission with HCV. About 25% of HIV infected individuals are co-infected with 
HCV, which is about 1.2 million people in the US [52]. According to meta-analysis studies, 
individuals co-infected with HIV/HCV are three times more likely to develop liver complications 
such as cirrhosis and liver cancer compared to those only infected with HCV[53]. HIV/HCV co-
infection also decrease the probability an individual will be able to spontaneously clear HCV [54]. 
Both HCV and HIV viruses produce “quasipecies” over the course of chronic infections due to 
random mutations made during replication. In both infections, only a few founder viruses are 
required to establish systemic, chronic infections. This means the host immune system needs to 
successfully clear and control the virus early on in the infection to prevent establishment and 
systemic spread [55].  It is still not clear how the immune system controls viral replication during 
HIV/HCV co-infections, but it is a well-known that viral fitness in each infection depends on 
adaptive immune pressure leading to the development of escape mutations [53]. Most co-infection 
studies have been focused on the impacts of HCV infection on the natural history of HIV 
infections. There is limited knowledge about how the presence of HIV and the immune 
dysfunctions related to its infection effects the immune system’s ability to mount an effective nAb 
response against HCV. 
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2.0  OBJECTIVE 
HYPOTHESIS 
We hypothesize that the host immunity, especially HCV specific nAb plays an important 
role in controlling HCV 3a infection, but exerts a minimal impact on the elimination of HCV 1a 
infection.  
  
SPECIFIC AIMS: 
To test our hypothesis, we have the following two specific aims:   
1. To construct and produce pseudoviruses carrying autologous HCV envelope proteins 
representing genotype 3a and genotype 1a derived from a study subject 
2. To evaluate neutralizing activity of the patient’s serum samples against the  
pseudovirusescarrying autologous HCV envelope proteins 
 
2.1.1 A CASE-STUDY REPORT 
The plasma/serum samples used in this study are from a participant of the Multicenter 
AIDS Cohort Study (MACS) in Pittsburgh. The MACS was designed to study the natural history 
of HIV infection and AIDS development and conducted at four cities, Los Angeles, Baltimore, 
Chicago and Pittsburgh. In this ongoing prospective cohort study homosexual and bisexual men 
were recruited to participate in the study.  They have their regular checkup and give their biological 
specimens biannually.   
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Over the past two years our research group has been involved in the study of HCV 
transmission and evolution in HIV/HCV coinfected MACS participants. Our study revealed one 
HIV/HCV coinfected individual with unusual disease course, which provides a unique opportunity 
to study humoral immune response against two HCV subtypes under the same immune 
environment [5]. This patient has been infected with HIV since 1987 and went under antiretroviral 
therapy in 1996. In 1997 at his regular biannual visit 27, HCV was first detected in his plasma with 
very high HCV load/undetectable HIV load/low CD4 count (Table 1). Comprehensive HCV 
screening and sequence analysis with his plasma samples reveal that this patient harbored HCV 3a 
at visit 27. However, starting from visit 30 (one and half years from visit 27), HCV 3a was 
undetectable and instead high levels of HCV 1a was detected in this patient’s plasma sample. 
Furthermore, HCV genotype 1a was consistently detected in his plasma samples in his subsequent 
visits (Table 1, Figure 4 and 5). This data suggest that HCV 3a was spontaneously cleared within 
1.5 years post infection from this individual, but he was subsequently infected again with HCV 1a, 
which established chronic infection. It is unclear which host immunity factors contributed to HCV 
3a clearance and why HCV 1a established chronic infection in the same host with the same immune 
environment.  
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Table 1. Patient’s detailed records with laboratory data. 
Visit - N CD4 count HIV (cp/ml) HCV (cp/ml) HCV genotype 
27 171 Undetected 33,021,250 genotype 3a 
30 272 Undetected 603,250 genotype 1a 
31 491 Undetected 2,165,750 genotype 1a 
32 333 Undetected 522,500 genotype 1a 
33 264 Undetected 640,250 genotype 1a 
40 352 Undetected 1,378,000 genotype 1a 
43 321 Undetected 772,000 genotype 1a 
 
 
 
Figure 4 Neighbor-joining tree of HCV E1/E2. 
The phylogenetic tree was constructed from HCV E1/E2 sequences amplified from the plasma samples of visit 27, 
visit 30 and visit 32 of the study subject. The bottom empty squares representing the sequences from visit 27 were 
clustered separately from other sequences of three other visits. The circles shown in red, green and black on the top 
are representing the sequences from 3 different visits 30, 31, and 32, which were clustered into a separate clade. 
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Figure 5 Phylogenetic tree of HCV E1/E2 sequences. 
The E1/E2 sequences of HCV genotypes 3a and 1a retrieved from HCV sequence database were aligned against this 
subject’s HCV E1/E2 sequences from visit 27 and visit 30, 31, and 32. Two clusters are formed: one with HCV 
genotype 3a at the bottom shown in black arrow and one with genotype 1a on top with black arrow. 
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3. MATERIALS AND METHODS 
3.1. STUDY SUBJECT AND PLASMA/SERUM SAMPLES 
Our previous study reveals one HIV/HCV co-infected Pittsburgh MACS participant with 
unique HCV infection course. In this study, we further investigated the immune response against 
HCV in this particular patient. The cryopreserved plasma/serum samples collected from this 
subject at his visit 27, visit 30 and visit 32 were used to amplify HCV envelope genes and perform 
the neutralization experiments.  
3.2 CELLS 
HCV permissive Huh-7.5.1 cells derived from human hepatocellular carcinoma were 
maintained in Dulbecco’s Modified Eagle Medium with 10% heat inactivated fetal bovine serum 
(FBS), 0.1mM non-essential amino acids and penicillin/streptomycin at 37 0 C and 5% CO2. 
Human epithelial kidney (HEK) 293T cells were propagated in Dulbecco’s Modified Eagle 
Medium with 10% FBS and penicillin/streptomycin at 37 0 C and 5% CO2. 
3.3. RNA EXTRACTION AND REVERSE TRANSCRIPTION 
Total nucleic acids were extracted from the cryopreserved plasma samples using the 
automatic Nuclisense EasyMag nucleic Acid extraction machine (bioMerieux, Durham, NC). 
Extracted nucleic acids (25ul) were used for Reverse Transcription with 0.25μM HCV sequence-
specific RT primer 5’ GGGCAGDBCARRGTGTTGTTGCC. Reverse transcription reaction was 
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performed using SuperScript® III Reverse Transcriptase according to manufacturer’s instruction 
(Applied Biosystems ).  
 
Table 2 HCV Core/E1/E2 primer sequences. 
 
 
 
 
 
 
3.4. PCR AMPLIFICATION OF HCV ENVELOPE GENE AND CLONING AND 
SEQUENCING THE PCR PRODUCT 
The synthesized cDNA was used for PCR amplification of HCV envelope gene. To obtain 
a complete gene expression cassette, the translation start codon ATG was incorporated into the 5’ 
primer and stop codons were included into 3’ primer (Table 2). 
The intact ORF of HCV core-E1-E2 was amplified from the cDNA with the designed 
primer pairs (Table 2), which generated 2.2kb PCR product. The PCR was performed by using 
high fidelity pfx DNA polymerase (Life Technologies) with the following thermo-cycling 
conditions: initially 95C for 10 minutes, then 35 cycles of denaturation 95C for 40 seconds, 
annealing 55C for 40 seconds, extension 68C for 2.5min with final extension 68C for 5minutes.  
The PCR product was run in a 0.8% agarose gel and visualized under UV light. The 2.2kb 
DNA band in the agarose gel was excised and extracted using Ultra-CleanTM DNA purification kit 
PRIMERS SEQUENCES 
HCV 3a Forward Primer ATGAGCACACTTCCTAAACCTCAAAG 
HCV 3a Reverse Primer CGCTTCTGCTTGTGTGATATCATCAGC 
HCV 1a Forward Primer ATGAGCACGAATCCTAAACCTAAAG 
HCV 1a Reverse Primer CGCCTCCGCTTGGGATATGA 
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(name of the company) according to manufacturer’s instructions. The extracted DNA was cloned 
into Topo blunt-end vector following manufacturer’s protocols (Zero Blunt TOPO PCR cloning 
Kit, Life Technologies). Briefly, the TOPO vector and PCR product ligation mixture was 
incubated in room temperature for 20 minutes followed by transformation of the mixture into 
competent E. Coli DH5α™. The transformed cells were plated onto agar plate with Kanamycin, 
which was incubated overnight at 37C.   The colonies grown on the agar plate were picked up and 
grew in LB broth with kanamycin overnight shaking in a warm room. Plasmids were purified with 
QIAprep Spin Miniprep Kit (Qiagen). The purified plasmid DNA was sent to University of 
Pittsburgh Genomics and Proteomics Core Laboratories for sequencing with commercial available 
M13 Forward and Reverse primers. The sequence results were analyzed with Vector-NTI program 
to check for the intactness of Core/E1/E2 ORF. There are no frame shift mutations or stop codons 
in the ORF of the envelope gene generated from all three visits’ plasma  
3.5. CLONING OF CORE/E1/E2 ORF INTO PROTEIN EXPRESSION VECTOR 
The Topo vector plasmid with the 2.2kb HCV core-E1-E2 gene were subjected to enzyme 
digestion by Not I and Spe I, for which, there are unique cutting sites flanking the 2.2kb insert in 
the TOPO vector. The expression vector VR1012 (a gift from Dr. Bindong Liu, Meharry Medical 
College in Nashville) was digested with Xba I and Not I. All the digestion reactions were carried 
out for 1hour in 37 0 C. Digested products was run in a 0.8% agarose gel, the 2.2kb DNA band 
from TOPO vector with insert and 4.9kb DNA band for the VR1012 were excised from the gel 
and the DNA was extracted with a Ultra-CleanTM DNA purification kit. The extracted 2.2kb and 
4.9kb DNA was ligated to create the VR1012 with the 2.2kb insert with Fast-link DNA ligation 
kit (Illumina corporation) according to manufacturer’s protocol. Then ligation mixture was 
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transformed into E.Coli DH5α™ competent cells and plated on agar plate with kanamycin and 
incubated in 37 0 C overnight. The colonies grown on the plate were picked up for colony PCR 
with the primers specific for Core/E1/E2 2.2kb insert. The 2,2kb positive colonies were cultured 
in LB broth followed by the plasmid extraction using QIAprep Spin Miniprep Kit. The purified 
plasmid DNA was digested with Not I and visualized after electrophoreses in a 0.8% agarose gel 
to check the size of the plasmid after ligation (Figure 6).  
 
 
 
  
Figure 6 Schematic diagram for plasmid construction. 
3.6. TRANSFECTION AND MEASUREMENT OF HCV PROTEIN EXPRESSION  
HEK 293T Cells were transfected with the cloned VR1012 expression vectors carrying 
HCV core/E1/E2 gene in the presence of Lipofectamin-2000. The cells were seeded in the 6-well 
plates with 106 cells/per well one day prior to transfection in DMEM supplemented with 10% FBS 
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without antibiotics. Equal amount (2.4ug) of plasmid DNA was used for all constructed plasmids 
to achieve the equal expression levels of HCV envelope proteins. In addition, the plasmid 
containing GFP gene was used as a control for monitoring the transfection efficiency. The plasmid 
transfections using Lipofectamin 2000 were performed following the protocol provided by the 
manufacturer (Life Technologies).  After 6 hours’ incubation in an incubator, the media was 
changed with fresh 10% DMEM/FBS containing pen/strep and the transfected cells were incubated 
in 37 0 C and 5% CO2 for additional 72 hours. Then the transfected cells were lysed and measured 
for HCV protein expression by Western blotting. 
The cell lysate was prepared by lysing the cells with 1x SDS lysing buffer and 2x loading 
buffer. The samples were boiled for 5 minutes and run in a 12% pre-cast gels (Mini-PROTEAN® 
TX- Precast Gels, Biorad), followed by transferring the proteins onto a nitrocellulose membrane. 
The membranes were blocked in the blocking buffer (phosphate-buffer saline (PBS) containing 
0.1% Tween-20 and 5% non-fat dried milk) for one hour in room temperature. Then the 
membranes were incubated overnight with rocking at 4C with C7-50, the mouse anti HCV core 
antigen monolclonal antibody (Pierce Thermo Scientific) in 1:1000 dilution with PBS containing 
0.1% tween-20 and 1% non-fat dried milk. After washing with PBS and 0.1% tween-20, the 
membranes were incubated with secondary antibody, goat anti-mouse IgG (Pierce Thermo 
Scientific) with 1:15000 dilution for one hour followed by washing. The protein bands were 
detected with SuperSignal chemiluminescent reagent (Pierce, Rockford, IL) and visualized by 
exposing to X-ray film.  The amount of α-tubulin was also visualized in the same membrane and 
used as a loading control.  
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3.7. HCVpp PRODUCTION AND INFECTIVITY ASSAY 
The expression plasmid VR1012 carrying HCV Core/E1/E2 gene together with the 
plasmids in second generation lentiviral packaging system including dr8.2 CMV encoding HIV 
gag/pol proteins and pTrip-luc was transfected into 293T cells using Lipofectamin-2000 (Figure 
4). The plasmid expressing GFP was used as a transfection control and VR1012 only as a negative 
control for HCVpp infectivity assays. 
The 293T cells were seeded into the 6-well plate with 1 x 106 cells /per well one day before 
transfection in DMEM supplemented with 10% FBS without antibiotics. The plasmids were 
transfected into 293T cells in the presence of Lipofectamin-2000. After 6 hours’ incubation, 
medium was changed with 10% DMEM/FBS and pen/strep media and the cells were incubated in 
37 0 C and 5% CO2.  Culture supernatant was collected at 24hours, 48hours and final 72hours post 
transfection for HIV p24 antigen measurement. Also, at 48hours and 72hours culture supernatant 
was collected, filtered through a 0.45-μm membrane and stored at -80C for HCVpp infectivity 
assay.   
To measure the HCVpp infectivity, Huh-7.5.1 cells (susceptible for HCV infection in vitro) 
were plated at 2 x 103 cells per well in a 96 well plate 24h before infection in DMEM supplemented 
with 10% FBS, 1% nonessential amino acids and antibiotics. The culture supernatant containing 
HCVpp was added to the Huh7.5.1 cells with 4ug/ml polybrene and incubated for 48h in 370C. 
Then, the medium was removed and the cells were lysed with 1x cell lysis buffer (Promega, 
Madison, WI).  After addition of luciferase substrate into the cell lysate, the firefly luciferase 
activity was measured in a luminometer (Veritas, Microplate Luminometer).   
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   Figure 7 Schematic picture for HCV pseudovirus production 
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3.8. NEUTRALIZATION ASSAY WITH HCVpp BEARING AUTOLOGOUS HCV 
ENVELOPE PROTEINS AND PATIENT’S SERA  
Serum neutralization activity was assessed by the luciferase activity in the Huh7.5.1 cells 
infected by HCVpp with or without pre-incubation with autologous serum. Huh-7.5.1 cells were 
seeded into a 96 well plate with 2 x 103 cells per well 24h prior to the infection. The serial 10 fold 
diluted heat-inactivated serum starting from 1:10 dilution was incubated with equal amount of 
HCVpp supernatant at 37C for 1 hr. After incubation the virus and serum mixture were added to 
the Huh-7.5.1 cells and incubated for 48h in 37C. Then the medium was removed and the cells 
were lysed with the cell lysing buffer (Promega, Madison, WI). After addition of luciferase 
substrate into the cell lysate, the firefly luciferase activity was measured in a luminometer. All the 
samples were run in duplicates or triplicates and the average of each sample’s RLU was calculated. 
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5.0 RESULTS 
Specific AIM-1: Construct and produce pseudoviruses carrying autologous HCV envelope 
proteins representing genotype 3a and genotype 1a 
5.1 CLONING OF HCV CORE/E1/E2 GENE INTO EXPRESSION VECTOR  
The schematic diagram of constructing the expression plasmids carrying HCV envelope 
gene is shown in Figure 6.  Expression vector VR1012 (a gift from Dr. Bindong Liu, Meharry 
Medical Cllege in Nashville) was used in the construction. Plasma RNA was isolated from the 
patient’s plasma samples collected at visit 27, visit 30 and visit 31 and was subjected to PCR to 
amplify HCV core/E1/E2 region with primers containing ATG and TAG at the respective ends. 
The 2.2kb PCR product containing HCV core/E1/E2 gene (Figure 8) was cloned into TOPO vector 
(Zero-blunt, Topo, Life Technologies) and sequenced with commercially available M13 
forward/reverse primers. The sequence analysis showed there were no frameshift mutations or stop 
codons within the cloned Core/E1/E2 ORF in all 3 visits. 
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                    Figure 8  The  PCR products of 2.2kb of HCV Core/E1/E2 
 
The Topo vector carrying the core/E1/E2 gene was digested with restriction enzymes Not 
I and Spe I (Figure 6). The protein expression vector VR1012 was digested with Not I and XbaI.  
Then the digested products of 2.2kb core/E1/E2 gene and 4.9kb linearized vector VR1012 (Figure 
9) were ligated to form the expression vector carrying HCV core/E1/E2 ORF (Figure 6).  Then, 
the ligation mixtures were transformed into competent cells and the colony PCR was performed 
in the following day with the primers amplifying the 2.2kb insert. A 2.2kb PCR product was 
confirmed in all 3 plasmids (Figure 10). Subsequently, All 3 purified expression plasmids carrying 
core/E1/E2 ORF from Visit 27, visit 30 and visit 32 were digested with restriction enzyme Not I 
to confirm the ligation (7.2 kb) (Figure 11). 
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Figure 9 Enzymatic digestion of plasmids 2.2kb and 5kb 
 
 
 
Figure 10 Colony PCR for 2.2kb insert with all 3 ligated plasmids from v27, v30 and v32 
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          Figure 11 Enzyme digestion of expression plasmid after ligation 
 
5.2 HCV PROTEIN EXPRESSION IN 293T CELLS 
Transfection of the constructed expression plasmids bearing HCV Core/E1/E2 into HEK 
293T cells was performed to monitor HCV protein expression in the transfected cells. Equal 
amounts of individual plasmid DNA was used for transfecting 293T cells in the presence of 
Lipofectamin-2000. GFP plasmid was also included in the experiment as a transfection control to 
make sure that DNA was getting transfected into 293T cells. At 48h post transfection, 60-70% of 
the cells were positive for GFP as shown in Figure 12. After 72 hours post transfection, the 
transfected cells were lysed and Western Blot was performed with the cell lysate with anti-HCV 
core antibody (Figure 13).  Nearly equal amount of α-tubulin was detected in all the samples in 
the Western Blot (Figure 13). This result confirms that HCV proteins were produced and processed 
in the transfected cells. 
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Figure 12 293T transfected cells after 48h with GFP expression in a separate well 
 
 
 
 
 
 
       Figure 13 HCV Core (21kDa) protein expression.  
Expression plasmids carrying HCV Core/E1/E2 from all 3 visits were transfected into 293T cells and the cells 
were lysed after 72h incubation. Western Blot was performed with the cell lysate to detect HCV Core (21kDa) . 
Subsequently, the Western blot membrane was stripped and re-probed with α-tubulin (55kDa).   
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5.3.HCV PSEUDOPARTICLE PRODUCTION (HCVpp)  
To produce HCV pseudoparticles bearing HCV envelope (HCVpp),  expression plasmid 
with Core/E1/E2 genes were cotransfected with lentiviral expression plasmids pCMVΔR8.2 and 
pTrip into 293T as described in the Materials and Methods. The plasmid pCMVΔR8.2 encoding 
HIV Gag and Pol proteins is responsible for particle budding at the plasma membrane. Whereas 
the plasmid pTrip contains a reporter protein Luciferase gene and the third plasmid is our 
constructed expression plasmid carrying patient’s HCV envelope gene, which provides envelope 
proteins for the pseudovirus. The vector control was used in this transfection experiment and it 
was co-transfected with pCMVΔR8.2 and pTrip as well. Cell culture supernatant was collected at 
24hrs, 48hrs and 72hrs post transfection and measured for HIV p24 antigen production by ELISA.  
The mean p24 values from 2 independent experiments are shown in Figure 13. This result 
indicates that HCVpp was produced, and the production of HCVpp in supernatants was peaked at 
72h post transfection. Overall the levels of HIV- p24 production from all 3 plasmids were very 
compatible (Figure 14). 
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       Figure 14 HIV p24 production from lentiviral packaging system. 
Average quantifications of p24 from 2 independent transfection experiments are shown. Supernatants were 
collected at 24h, 48h and 72h post transfection.  
5.2 SPECIFIC AIM 2 RESULTS 
Specific AIM-2: To evaluate neutralizing activity of the patient’s serum samples with the 
produced HCV pseudoparitcles carrying autologous envelope proteins 
5.2.1 Evaluation of HCVpp Infectivity in Huh7.5.1 cells 
To determine the infectivity of the produced pseudoparticles carrying autologous HCV 
Core/E1/E2 proteins, the culture supernatants containing HCVpp were tested for infectivity in 
HCV susceptible cells.  The culture supernatant containing HCVpp was incubated with Huh-7.5.1 
cells in the presence of polybrene for 48hrs followed by measurement of luciferase activity in the 
cell lysate. The results are shown in Figure 15. 
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 Figure 15 HCVpp infectivity on Huh-7.5.1 cells. 
50ul of culture supernatant containing HCVpp from 3 different visits were individually added to Huh-7.5.1 cells with 
80% confluency in the presence of polybrene. The Relative Light Unit (RLU) was measured in cell lysate 48hrs post 
transfection. The mean quantities of RLU from of 6 independent experiments are shown. 
 
5.2.2 Evaluation of neutralizing activity of the patient’s serum against the produced 
HCVpp with autologous HCV envelopes. 
In order to evaluate the neutralizing activity in patient’ serum, HCVpp from each visit was 
used to infect Huh 7.5.1 cells with or without pre-incubation with three corresponding visit serum 
samples individually as shown in Figure 16. Relative Light Unit (RLU) was measured for 
calculating the neutralization activity of the serum against the HCVpp, 
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 Figure 16 Schematic diagram of Neutralization experiment 
 
The same amount of HCVpp was pre-incubated at 37C for 1 hour with serial 10 fold 
dilutions of serum samples. The mixture was added to Huh-7.5.1 cells and incubated for additional 
48hrs and then the cells were lysed for luciferase activity measurement. Neutralization activity 
was calculated by the reduction of RLU. For each serum dilution, the neutralization experiments 
were run in duplicates.  
The results in Figure 17 show that RLU detected in the HCVpp infected cells were not 
significantly different with or without presence of serum, which indicates that there are no 
significant neutralizing activity in all the serum against the HCVpp. However, there are some 
reductions in RLU when HCVpp v27 was pre-incubated with v28 serum. Serum at visit 28 was 
still HCV 3a and we used that sera to measure neutralization activity against HCVpp from v27 
represented genotype 3a (Figure 17).  
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Figure 17 Neutralization of HCVpp with serially diluted serum samples.  
Serial 10 fold dilution of sera obtained at visit28, visit30 and visit32 were tested against corresponding HCVpp. 
Average reduction in RLU from  one experiment in duplicates is shown 
 35 
6.0 DISCUSSION 
During acute HCV infection HCV-specific nAb’s develop late after T cell immune 
response suggesting their role in HCV clearance questionable. There is a big debate among HCV 
scientists regarding to the role of humoral immune response in HCV infection and clearance. Some 
authors have shown the importance of nAb’s in virus clearance, whereas others provide evidence 
for minimal role of nAb’s in the resolution of HCV infection. According to early chimpanzee 
studies, mammalian cell-derived recombinant HCV E1 and E2 glycoproteins were able to induce 
an effective protective immune response. After a high dose of viral challenge, the immunized 
chimpanzees were able to clear the virus before developing a chronic or acute HCV infection [56]. 
Other previous studies have also shown the importance of neutralizing antibodies in the protection 
against HCV infections. When viral inoculum was pre-incubated with human anti-HCV sera and 
immunoglobulin and injected into chimpanzee models, the monkeys did not develop HCV 
infection in response to this viral challenge [57, 58]. These findings imply that broadly neutralizing 
antibodies play an important role in preventing the monkeys from HCV infection.  
Some authors reported that nAb’s are not required for HCV clearance [59]. According to 
chimpanzee studies during acute HCV infection the response against HCV hypervariable region 
in E2 leads to chronic infection, instead of viral clearance . Also, other studies have shown that the 
broadly neutralizing antibodies were present in the serum of chronically infected patients 
suggesting that they do not mediate HCV clearance[60-62]. 
Approximately 25% of HCV infected people spontaneously clear the infection, which 
provides the opportunity to study how human immune system effectively eliminate the virus. In 
this study, the HCV 3a were cleared, whereas subsequent HCV 1a infection established a chronic 
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infection in the same co-HIV/HCV infected subject, which provides us a chance to study the 
immune response against two HCV genotype infections with different infection outcomes. 
Comparing the host immune responses against these two genotype viruses may lead to the 
significant findings of the host factors responsible for the HCV clearance. 
The development of in vitro study systems for studying HCV life cycle and replication has 
been a long process with limited progress since the isolation of viral cDNA in 1989 [22] and the 
availability of first  HCV cDNA clone  in 1997[63]. Currently, with few exceptions, HCV still 
could not efficiently infect and replicate in the target cells in in vitro condition. Through the work 
of HCV protein’s structural biology the full-length genomic HCV replicons were developed, but 
they were unable to infect susceptible cell lines[64]. In 2005, the isolation of HCV RNA from a 
patient with Japanese fulminant hepatitis genotype 2a enabled the researchers to construct an 
infectious molecular clone of HCV (JFH-1) for studying HCV replication cycle in susceptible 
cells[23]. Followed by this advances, the number of other infection systems have been advanced 
too[11].  However, for some unclear reasons, these in vitro produced HCV have lower infectivity 
compared to JFH-1 and quickly develop cell culture-adaptive mutations [65].  
Another breakthrough in HCV study models was the development of HCV pseudoparticles 
(HCVpp)[4]. This system works by incorporating unmodified HCV glycoproteins E1 and E2 onto 
retroviral particles, which bypasses the hurdle of growing HCV in the lab [66] and enables 
scientists to study HCV entry and antibody neutralization activity in vitro. With the HCVpp 
system, reproducible results have been acquired in studying the neutralizing antibody responses in 
HCV infections [4], suggesting that HCVpp system is suitable for studying immune responses 
against HCV. Up to now, in most of the studies, the HCVpp was produced by incorporating E1 
and E2 of H77 or other available HCV into retroviral particles, which is not optimal for measuring 
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anti HCV activity in patient serum since each individual patient harbors its unique HCV E1 and 
E2 sequence.  
In this study we investigated the role of neutralizing antibodies in HIV/HCV co-infected 
individual where HCV genotype 3a was naturally resolved, even though it has been proved that 
HIV infected people have less chance to clear HCV infection [3].  However, the subsequent 
infection with HCV genotype 1a led to chronicity. It is more likely that in this particular HIV/HCV 
co-infected individual, the host immunity handles differently the two sequential HCV infections 
with genotypes 1a and 3a. To accurately measure the antibody responses against these two 
sequential HCV infections, we constructed and produced the HCVpp by incorporating autologous 
HCV E1 and E2 of 3a and 1a detected in this patient’s plasma instead of using the commercial 
available H77 envelope genes. Then we measured the neutralization activity of patient’s serum 
with the produced autologous HCVpp.  
We produced autologous HCVpp representing HCV genotypes 3a and 1a extracted from 
patient’s plasma as shown in schematic diagram in Figure 7. The infectivity of the produced 
HCVpp was observed in Huh-7.5.1 cells suggesting that the HCVpp enters the cells similar to the 
entry stepof the HCV life cycle and could be used  for neutralization experiments (Figure 15). 
Following the confirmation of infectivity on susceptible cell lines we proceeded to measure the 
neutralizing activity of this patient’s serum against the autologous HCVpp represented HCV 
genotype 3a and 1a. Our results   showed that there is some, but non-significant neutralizing 
activity detected in patient’s serum against HCVpp genotype 3a, whereas for HCVpp genotype 1a, 
no neutralizing activity was detected in patient’s serum (Figure 17). This result is consistent with 
previous reports that for some unknown mechanism, there is a higher spontaneous clearance rate 
of HCV 3a infection than that of 1a [67].  
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In conclusion, the neutralizing activity against autologous HCV in patient’s serum could 
be studied more accurately by constructing and producing the HCVpp carrying autologous HCV 
E1 and E2 proteins. Using this assay, we were able to demonstrate that in this HIV/HCV co-
infected person’s serum low level of neutralizing activity against HCVpp genotype 3a was 
detected, but no neutralizing activity was detected against HCV genotype 1a. By using this 
experimental approach we could expand our knowledge in the future in obtaining new information 
on the interactions between HCV and neutralizing antibodies. 
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7.0 LIMITATIONS AND FUTURE DIRECTIONS 
Despite the fact that HCVpp were successfully produced with patient’s autologous HCV 
envelope proteins of genotype 1a and 3a, their infectivity on Huh-7.5.1 cells was not high although 
multiple transfections followed by infection had been performed. However, other researchers also 
reported similar low infectivity of HCVpp. It has been speculated that the 293T cells used for 
producing HCVpp lack lipid metabolism as a result HCVpp do not have association with any host 
lipoproteins like in serum-derived HCV virions [12, 68], which leads to the low infectivity.  If the 
HCVpp infectivity remains low in the future study, the primary human liver cells will be used   to 
increase the infectivity for accurate measurement of neutralizing ability of sera [24]In the future 
studies, the patient’s serum samples from different visits will also tested for neutralizing activity 
against all constructed HCVpp to evaluate the neutralization activity in the serum with a broader 
range.   
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8.0 PUBLIC HEALTH SIGNIFICANCE  
Currently there are no vaccines available against HCV infection and it should be prioritized 
to explore the vaccine development approaches by understanding the mechanisms of the natural 
HCV clearance. In 2010 Food and Drug Administration approved the use of direct acting antiviral 
agents against HCV proteases, and in 2014 new effective drugs became available against HCV 
infection [69]. However, due to its high cost ($84-130.000 per course of treatment) it will be a 
high economic burden and will be impossible to provide all infected patients with the new therapy. 
Therefore, the development of an effective and low cost vaccine will be the ideal method to prevent 
HCV infection. In this current study, he role of neutralizing antibodies during natural resolution 
of HCV infection is studied. The results reported in this study showed the minimal neutralizing 
activity in the patient’s serum with the HCV clearance, which needs to be further explored in order 
to fully understand its mechanisms. 
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